로딩 중…
지수 로딩 중…
큐라티스
348080· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩418+8.57%
2026-06-19
Price Chart
큐라티스-59.34%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 48.26B KRW |
| Revenue | 1.26B KRW |
| Net Income | -30.97B KRW |
| Total Assets | 61.30B KRW |
| Net Assets | 50.30B KRW |
| Employees | 72 |
| Value | |
| P/B | 0.96x |
| P/S | 38.43x |
| FCF Yield | -26.50% |
| Profitability | |
| ROE | -61.57% |
| ROA | -50.53% |
| Op. Margin | -802.99% |
| Revenue Growth | -99.22% |
| Financial Health | |
| Debt Ratio | 121.86% |
| Total Debt | 9.43B KRW |
| FCF | -12.79B KRW |
| Cash | 14.42B KRW |
| Current Ratio | 1.49x |
| Performance | |
| 1Y Return | -59.34% |
| 1M Return | -28.18% |
| From 52W High | -71.85% |
| 1Y MDD | -72.79% |
| Trading | |
| Volume | 772,619 shares |
| Foreign Own. | 3.25% |
| Per Share | |
| EPS | -388 KRW |
| BPS | 436 KRW |
Company Info
Established in 2016, this company possesses vaccine development platform technology and was listed on KOSDAQ in 2023. It is developing preventive vaccines for adult and adolescent tuberculosis, schistosomiasis, and next-generation mRNA COVID-19, operating manufacturing facilities and research laboratories that meet cGMP, EU-GMP, and KGMP standards. Utilizing its vaccine development platform technology, the company conducts the entire new drug development process and offers services and consulting to bio new drug development clients. Curatis, established in 2016, is headquartered in Chungcheongbuk Province, Cheongju City.